Type II Collagen-induced Arthritis in Mice. III. Suppression of Arthritis by Using Monoclonal and Polyclonal Anti-Ia Antisera

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 1985 Apr 1

PMID 3855932

Citations 19

Authors

P H Wooley

H S Luthra

W P Lafuse

A Huse

J M Stuart

C S David

Affiliations

Soon will be listed here.

Abstract

Pretreatment of mice genetically susceptible to type II collagen-induced arthritis (CIA) with monoclonal or polyclonal antisera specific for I region gene products (Ia antigens) suppressed or delayed the onset of CIA, whereas pretreatment with anti-Ia to an irrelevant haplotype was without effect. The humoral response to type II collagen was transiently depressed 14 days after immunization but antibody levels did not differ significantly after 28 days. The peak delayed-type hypersensitivity to type II collagen was unaffected by anti-Ia treatment. Monoclonal antibody of one anti-Ia specificity enhanced both the antibody response and the arthritis incidence in one mouse strain.

Citing Articles

Complement in the Initiation and Evolution of Rheumatoid Arthritis.

Holers V, Banda N Front Immunol. 2018; 9:1057.

PMID: 29892280 PMC: 5985368. DOI: 10.3389/fimmu.2018.01057.

Resistance to development of collagen-induced arthritis in C57BL/6 mice is due to a defect in secondary, but not in primary, immune response.

Pan M, Kang I, Craft J, Yin Z J Clin Immunol. 2004; 24(5):481-91.

PMID: 15359107 DOI: 10.1023/B:JOCI.0000040919.16739.44.

The genetic and immunopathological processes underlying collagen-induced arthritis.

Luross J, Williams N Immunology. 2001; 103(4):407-16.

PMID: 11529930 PMC: 1783255. DOI: 10.1046/j.1365-2567.2001.01267.x.

New therapies in development for autoimmune diseases: their rationale for combination treatment.

Strand V Springer Semin Immunopathol. 2001; 23(1-2):43-61.

PMID: 11455860 DOI: 10.1007/s002810100071.

Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?.

Williams R Springer Semin Immunopathol. 1998; 20(1-2):165-80.

PMID: 9836375 DOI: 10.1007/BF00832005.